Viridian Therapeutics price target lowered to $45 from $48 at Wedbush

Wedbush lowered the firm’s price target on Viridian Therapeutics to $45 from $48 and keeps an Outperform rating on the shares. The firm sees VRDN-001 demonstrating efficacy in chronic and active TED populations and the firm also sees a better differentiation opportunity versus Tepezza with Phase 3 studies underway and the THRIVE study now emphasizing a more compact dosing scheme, the analyst tells investors in a research note.